Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

COQUILLE VALLEY HOSPITAL

UEI: MKXYHLK3H8Q4CAGE: 5RP87

COQUILLE VALLEY HOSPITAL is a federal contractor, registered under UEI MKXYHLK3H8Q4 and CAGE code 5RP87. It has been awarded $387,524 across 3 federal contracts. Primary work spans Unknown NAICS. Top awarding agencies include Department Of Health And Human Services (hhs).

Contact Information

Registration and classification details

Registration

UEI Code

MKXYHLK3H8Q4

CAGE Code

5RP87

Entity Structure

Corporate Entity (Tax Exempt)

Established

N/A

Business Classifications

2U80

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

COQUILLE VALLEY HOSPITAL operates as a healthcare delivery entity serving the local community in Coquille, Oregon. As a facility providing direct patient care, its core capabilities encompass clinical services including emergency care, primary care, diagnostic imaging, laboratory testing, and inpati...

COQUILLE VALLEY HOSPITAL operates as a healthcare delivery entity serving the local community in Coquille, Oregon. As a facility providing direct patient care, its core capabilities encompass clinical services including emergency care, primary care, diagnostic imaging, laboratory testing, and inpatient management. The organization is structured to deliver comprehensive, community-based healthcare under standard medical protocols, with a focus on operational continuity, regulatory compliance, and patient-centered care delivery. Its technical expertise lies in maintaining accredited healthcare workflows, implementing electronic health record systems, ensuring HIPAA compliance, and coordinating with regional public health networks. Specialization includes serving rural populations with limited access to specialized care, emphasizing telehealth integration, chronic disease management, and emergency response readiness. No award history is available to infer federal contracting activity or agency engagement. Consequently, there is no demonstrable track record of performance with federal, state, or municipal government agencies. The absence of contract data precludes identification of specific agency relationships or types of government-supported services delivered. No NAICS codes are associated with the entity’s contract history, indicating that COQUILLE VALLEY HOSPITAL does not operate as a government contractor under standardized procurement categories. Its market positioning is rooted in direct healthcare service provision rather than federal procurement markets. The entity is structured as an 8H organization, indicating it is a small business owned and operated by individuals of Native American heritage, though no formal government certifications such as 8(a), HUBZone, or SDVOSB are listed. Its geographic presence is localized to Coquille, Oregon, with operations focused on serving the immediate region’s healthcare needs rather than participating in broader federal procurement channels.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Department Of Health And Human Services (hhs)$387.5K100%
Awards by NAICS
- Unknown NAICS$387.5K100%
Awards by Agency Over Time
Export
Awards by Place of Performance

Open opportunities in COQUILLE VALLEY HOSPITAL's top NAICS codes and agencies

NAICS: 513210
New
Federal
Notice of Sole Source: GastroPlus PBPK and PBBM modeling platform subscription
Solicitation # 7571TE26Q00153
The U.S. Food and Drug Administration, through the Department of Health and Human Services, intends to sole-source a firm fixed-price contract to Simulations Plus Inc. for twenty GastroPlus and five DDDPlus software licenses, used for physiologically based pharmacokinetic and physiologically based biopharmaceutics modeling in support of generic drug research. The contract spans a base year from September 1, 2026, to August 31, 2027, with up to three one-year option periods extending through August 31, 2030. Performance will occur at the FDA’s White Oak campus in Silver Spring, Maryland. The acquisition is conducted under RFO 12, allowing for non-competitive procurement of commercial products, and no set-aside applies. Responses are due by August 14, 2026, and any interested party may submit a capability statement to demonstrate their ability to supply the exact software licenses as the original equipment manufacturer or authorized reseller, which the government will review solely to determine whether competitive procurement is warranted. The contract requires the vendor to provide standard individual licenses, with no auto-renewals permitted unless explicitly authorized. Acceptance of deliverables will be conducted by the Contracting Officer’s Representative within 30 working days of delivery, verifying software functionality, compatibility with FDA systems, and compliance with technical requirements. Invoicing must be submitted electronically through the Treasury’s Invoice Processing Platform, and all invoices must include detailed supporting documentation for labor, materials, and costs. The government retains the right to reject nonconforming deliveries and will not pay for services that fail to meet agreed standards. Clauses from the FAR and HHSAR govern payment, representation, whistleblower rights, anti-lobbying, accessibility, and dispute resolution, with federal regulations taking precedence over any vendor terms. The Contracting Officer and Contract Specialist are the primary points of contact, and all vendors must be actively registered in SAM at the time of submission.
Department Of Health And Human Services

POSTED

1 day ago

DEADLINE

in 9 days
View Details
NAICS: 541715
New
Federal
Antioxidant Therapy for Smith-Lemli-Opitz Syndrone
Solicitation # NICHD-08610
The contract pertains to the development and implementation of antioxidant therapy for Smith-Lemli-Opitz Syndrome, a rare genetic disorder characterized by multiple congenital anomalies and metabolic dysfunction. The solicitation, issued under NICHD-08610 by the Department of Health and Human Services through its National Institutes of Health, invites proposals aimed at advancing targeted antioxidant interventions to mitigate the pathological effects of the condition. The opportunity was posted on August 3, 2026, with responses due by August 18, 2026, at 2:00 PM Eastern Time. The work is expected to be performed in Bethesda, Maryland, consistent with the research infrastructure of the NIH campus. All proposals must be submitted through the SAM.gov portal and should address scientific rigor, feasibility, and potential clinical impact. The primary point of contact for inquiries is Niamh Cawley, with Chung Huang as the secondary contact, both reachable via NIH email addresses. The contracting activity falls under the Department of Health and Human Services with no set-aside provisions specified, and no NAICS code is assigned, indicating flexibility in contractor categorization. Interested parties should ensure adherence to deadlines and submission requirements outlined on the official UI link linked in the posting.
Department Of Health And Human Services

POSTED

2 days ago

DEADLINE

in 13 days
View Details
NAICS: 562111
New
Federal
Notice of Intent / Sole Source Solid Waste
Solicitation # 75H71026Q00223
The Navajo Area Indian Health Service, Shiprock Service Unit, intends to award a sole-source, firm-fixed-price contract to Navajo Sanitation for solid waste collection services at the Dzilth-Na-O-Dith-Hle Health Center in Bloomfield, New Mexico, with performance beginning September 1, 2026, and ending August 31, 2027. The procurement is justified under unusual and compelling urgency due to the contractor’s unique, uninterrupted history of providing essential waste management services at the facility, ensuring continuity of operations critical to patient care. The North American Industry Classification System code is 562111, with a small business size standard of $47 million in annual revenue. No competitive solicitation will be issued unless a respondent submits clear and convincing evidence that competition would benefit the government. Responses must be submitted in writing as a capability statement by August 17, 2026, at 10:00 a.m. MST, and must not include proprietary, classified, confidential, or sensitive information. The government is not obligated to respond to or acknowledge submissions, and failure to receive affirmative responses will result in contract award without further notice. All information provided may be used in future solicitations if competition is pursued, and any resulting solicitation will be publicly announced on SAM.gov. The point of contact for inquiries is Ken Parrish, Purchasing Agent, reachable at ken.parrish@ihs.gov.
Department Of Health And Human Services

POSTED

6 days ago

DEADLINE

in 13 days
View Details
NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
This solicitation supports Small Business Technology Transfer (STTR) grants through the National Institutes of Health to fund research and development projects that advance innovative technologies with potential for commercialization, requiring a formal collaboration between a U.S.-owned small business and a nonprofit research institution. The award is made solely to the small business, regardless of where the principal investigator is employed, and projects must align with the missions of NIH, CDC, or FDA components. Funding is available for Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with Fast-Track allowing combined Phase I and II review to streamline the process. Direct to Phase II is an option for businesses that have already demonstrated technical merit without prior Phase I funding, provided the application is submitted as a new proposal, not a renewal. Only one Phase II award is permitted per Phase I project, and Phase IIB Strategic Breakthrough applications must go through a separate solicitation. Applications must focus on feasibility or R&D that supports public health goals and are subject to restrictions on clinical trials, which are not permitted under this NOFO if exclusively aligned with specific NIH institutes including NIAID, NIAMS, NIDCR, NIDDK, NIMHD, NCATS, and ORIP. The funding opportunity is part of the broader SBIR/STTR mandate, which requires NIH to set aside 0.45% of its extramural budget for STTR, ensuring support for small businesses with fewer than 500 employees. Applicants are encouraged to consult with program staff prior to submission to ensure alignment with funding priorities and to use the Assignment Request Form to suggest an appropriate awarding component, though such identification is not mandatory. The solicitation closes on August 5, 2026, and information on program details, priorities, and frequently asked questions is available through the NIH Seed Fund portal and related government strategies including the Make Our Children Healthy Again initiative.
Department of Health and Human Services

POSTED

2 months ago

DEADLINE

in 8 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
This funding opportunity supports U.S. small businesses in advancing early-stage research and development toward commercialization through the SBIR program, administered by the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. Eligible small businesses must be U.S.-owned and operated with fewer than 500 employees and are expected to lead the majority of the technical effort, with the principal investigator primarily employed by the business. The program offers Phase I grants to establish technical feasibility, Phase II grants to advance development toward market readiness, and two special pathways: Direct to Phase II for projects with prior proof of concept but no prior Phase I award, and Fast-Track for combined Phase I and Phase II submissions reviewed concurrently to accelerate progress. All awards are granted to the small business, and commercialization must be pursued using non-SBIR funds after Phase II. The scientific scope must align with the missions of participating NIH, CDC, or FDA components, focusing on health improvement and public health innovation, with applicants encouraged to consult specific institute priorities and the White House’s Make Our Children Healthy Again Strategy. While clinical trials are permitted, they are explicitly excluded if the application aligns solely with certain NIH institutes or all FDA centers, making alignment critical for responsiveness. Applications must be submitted through the designated portal by the deadline, and while applicants are not required to specify an awarding component during submission, consultation with program staff beforehand is strongly advised to ensure proper alignment. The solicitation operates under a complete small business set-aside mandate and is open to new applications only, with no renewals accepted for Direct to Phase II submissions.
Department of Health and Human Services

POSTED

2 months ago

DEADLINE

in 8 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The Commercialization Readiness Pilot (CRP) program, issued under PAR-27-098, provides late-stage research and development funding and technical assistance to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award or a Phase IIB Strategic Breakthrough award. This initiative is designed to bridge the gap between Phase II completion and full commercialization by supporting activities that require significant outsourcing, such as regulatory strategy, intellectual property development, manufacturing optimization, pre-clinical product development, and clinical trials—though not all NIH institutes accept clinical trial proposals. The program permits substantial outsourcing to contract research organizations but requires the small business to maintain active oversight and management of all scientific, financial, and administrative aspects of the work, with justified budget allocations reflecting this role. CRP funding cannot cover FDA filing fees or include separate Technical and Business Assistance (TABA) funds. Eligible applicants must be small business concerns under 500 employees meeting SBA size standards, and proposals must align with the mission of participating NIH components. The solicitation explicitly excludes applications that propose clinical trials solely aligned with certain NIH institutes, including NHLBI, NIAID, NIDDK, and others listed, which do not accept such trials under this program. Applications are limited to Type 1 new submissions, and prior Phase II funding is mandatory for eligibility. Applicants are strongly encouraged to consult with NIH program staff before submitting to ensure alignment with the most appropriate funding mechanism, as the Phase IIB Strategic Breakthrough program (PA-27-101) may be better suited for some projects with matching fund requirements. The solicitation is active through August 5, 2026, under a total small business set-aside, and further details are available through the NIH SBIR/STTR portal.
Department of Health and Human Services

POSTED

2 months ago

DEADLINE

in 8 months
View Details